FDA: New Warning for Procrit, Epogen, Aranesp
New data show that the way Procrit, Epogen, and Aranesp are used in patients with chronic kidney disease puts them at risk of heart attacks, stroke, and death. More conservative dosing is needed.
Click here to read the full story.
No profanity or inappropriate comments will be allowed.
Offensive posters will be blocked from future postings.